



## Praxis Precision Medicines to Participate in TD Cowen's 44th Annual Health Care Conference

March 1, 2024 at 8:00 AM EST

BOSTON, March 01, 2024 (GLOBE NEWSWIRE) -- [Praxis Precision Medicines](#), Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will participate in the TD Cowen 44<sup>th</sup> Annual Health Care Conference, taking place in Boston from March 4 – 6, 2024. In addition to conducting one-on-one investor meetings, management will participate in a corporate panel discussion.

### **Panel Discussion Details**

Title: Orphan Epilepsies Corporate Panel Discussion  
Date: Wednesday, March 6, 2024  
Time: 10:30 a.m. EST  
Webcast Link: [Link](#)

This live webcast will also be available through the Events & Presentations page of the Investors + Media section of the company's website [www.praxismedicines.com](http://www.praxismedicines.com). A replay of the webcast will be available on Praxis' website for 90 days following the event.

### **About Praxis**

Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across movement disorders and epilepsy, with four clinical-stage product candidates. For more information, please visit [www.praxismedicines.com](http://www.praxismedicines.com) and follow us on [Facebook](#), [LinkedIn](#) and [Twitter/X](#).

Investor Contact: Praxis Precision Medicines [investors@praxismedicines.com](mailto:investors@praxismedicines.com) 857-702-9452 Media Contact: Dan Ferry Life Science Advisors [Daniel@lifesciadvisors.com](mailto:Daniel@lifesciadvisors.com) 617-430-7576